Cargando…

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

Venous thromboembolism (VTE) following breast cancer chemotherapy is common. Chemotherapy-induced alterations in markers of haemostasis occur during chemotherapy. It is unclear how rapidly this occurs, whether this is upregulated in patients developing VTE and whether changes predict for VTE. Marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirwan, C C, McDowell, G, McCollum, C N, Kumar, S, Byrne, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567096/ https://www.ncbi.nlm.nih.gov/pubmed/18766191 http://dx.doi.org/10.1038/sj.bjc.6604620

Ejemplares similares

Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer
por: Kirwan, Cliona C, et al.
Publicado: (2009)

Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
por: Kilic, Nevin, et al.
Publicado: (2012)

Inflammation, Haemostatic Disturbance, and Obesity: Possible Link to Pathogenesis of Diabetic Retinopathy in Type 2 Diabetes
por: Tomić, Martina, et al.
Publicado: (2013)

Chlamydia pneumoniae Antibodies and C-Reactive Protein Levels in Patients with Abdominal Aortic Aneurysms
por: Sharif, M. A., et al.
Publicado: (2013)

Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer
por: Bhattacharyya, M, et al.
Publicado: (2008)

A Randomized Clinical Trial Comparing the Effect of Different Haemostatic Agents for Haemostasis of the Liver after Hepatic Resection
por: Kakaei, Farzad, et al.
Publicado: (2013)

Suprarenal Extract as a Hæmostatic
Publicado: (1902)

Ovarian Tissue as a Hæmostatic in Hæmophylic Persons
por: Zavadier, S.
Publicado: (1903)

Significance of Haemodynamic and Haemostatic Factors in the Course of Different Manifestations of Cerebral Small Vessel Disease: The SHEF-CSVD Study—Study Rationale and Protocol
por: Staszewski, Jacek, et al.
Publicado: (2013)

Citrate does not Change Viscoelastic Haemostatic Assays after Cardiopulmonary Bypass
por: Kristobak, Benjamin M., et al.
Publicado: (2022)

Early but reversible haemostatic changes in a-symptomatic females expressing COVID-19 antibodies
por: Williams, J.O., et al.
Publicado: (2022)

Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours
por: Veal, G J, et al.
Publicado: (2007)

Hæmostatic Agents
Publicado: (1856)

Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy
por: Courneya, K S, et al.
Publicado: (2014)

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
por: Jones, A. L., et al.
Publicado: (1992)

Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
por: Hirata, T, et al.
Publicado: (2009)

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
por: Bengala, C, et al.
Publicado: (2006)

Effects of Cryopreservation on Microparticles Concentration, Procoagulant Function, Size Distribution, and Morphology
por: Dong, Xinlong, et al.
Publicado: (2019)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)
por: Cold, S, et al.
Publicado: (2005)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Simple clotting test to detect procoagulant abdominal swabs
por: Krajewski, Stefanie, et al.
Publicado: (2015)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
por: Poikonen, P, et al.
Publicado: (2005)

Comparison of the haemostatic properties of conventional monopolar and bipolar transurethral resection of the prostate in patients on oral anticoagulants
por: Michielsen, Dirk P.J., et al.
Publicado: (2011)

Ergotine as a Hæmostatic
Publicado: (1871)

A New Hæmostatic
Publicado: (1897)

Paresi’s Hæmostatic Collodion
Publicado: (1881)

A New Hæmostatic
Publicado: (1874)

Ipecac as a Hæmostatic
Publicado: (1878)

Ipecac as a Hæmostatic
Publicado: (1879)

Ergotine as a Hæmostatic
Publicado: (1872)

Antipyrin a Hæmostatic
Publicado: (1892)

Antipyrine as a Hæmostatic
por: Powell, W. M.
Publicado: (1888)

A New Hæmostatic
Publicado: (1885)

Gelatin as a Hæmostatic
Publicado: (1901)

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
por: Hennigs, A., et al.
Publicado: (2016)

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
por: Conte, P F, et al.
Publicado: (2005)

Haemostatic Changes in Five Patients Infected with Ebola Virus
por: Smither, Sophie J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8gn2gvfiphbnhvspbblf6qd736